Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2014

01-07-2014 | Case Report

An Association of Myeloproliferative Neoplasms and Obliterative Portal Venopathy

Authors: Jillian E. Mayer, Thomas D. Schiano, Maria Isabel Fiel, Ronald Hoffman, John O. Mascarenhas

Published in: Digestive Diseases and Sciences | Issue 7/2014

Login to get access

Excerpt

Obliterative portal venopathy (OPV) is a cause of non-cirrhotic portal hypertension (NCPH) and has recently replaced the term hepatoportal sclerosis, which is synonymous with idiopathic portal hypertension, non-cirrhotic portal fibrosis and incomplete septal cirrhosis [1]. There continues to be some confusion as to whether these terms refer to the same clinical entity [1]. OPV involves varying degrees of obliteration of the portal vein and particularly affects the small terminal branches of the intrahepatic portal vein [1]. Dilatation of the sinusoids, regenerative hepatic nodules, and extrahepatic portal vein involvement can also be seen [1]. …
Literature
1.
go back to reference Bioulac-Sage P, Le Bail B, Bernard PH, Balabaud C. Hepatoportal sclerosis. Semin Liver Dis. 1995;15:329–339.PubMedCrossRef Bioulac-Sage P, Le Bail B, Bernard PH, Balabaud C. Hepatoportal sclerosis. Semin Liver Dis. 1995;15:329–339.PubMedCrossRef
2.
go back to reference Okuda K. Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol. 2002;17:S204–S213.PubMedCrossRef Okuda K. Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol. 2002;17:S204–S213.PubMedCrossRef
3.
go back to reference Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33:313–320.PubMedCrossRef Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33:313–320.PubMedCrossRef
4.
go back to reference Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061.PubMedCrossRef Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061.PubMedCrossRef
5.
go back to reference Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002;51:275–280.PubMedCentralPubMedCrossRef Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002;51:275–280.PubMedCentralPubMedCrossRef
6.
go back to reference Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5:55–61.PubMedCrossRef Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5:55–61.PubMedCrossRef
7.
go back to reference Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113:5246–5249.PubMedCentralPubMedCrossRef Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113:5246–5249.PubMedCentralPubMedCrossRef
8.
go back to reference Boyer JL, Sen Gupta KP, Biswas SK et al. Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and extrahepatic portal vein obstruction. Ann Intern Med. 1967;66:41–68. Boyer JL, Sen Gupta KP, Biswas SK et al. Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and extrahepatic portal vein obstruction. Ann Intern Med. 1967;66:41–68.
9.
go back to reference Roskams T, Baptista A, Bianchi L, et al. Histopathology of portal hypertension: a practical guideline. Histopathology. 2003;42:2–13.PubMedCrossRef Roskams T, Baptista A, Bianchi L, et al. Histopathology of portal hypertension: a practical guideline. Histopathology. 2003;42:2–13.PubMedCrossRef
10.
go back to reference Hoekstra J, Bresser EL, Smalberg JH, Spaander MC, Leebeek FW, Janssen HL. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost. 2011;9:2208–2214.PubMedCrossRef Hoekstra J, Bresser EL, Smalberg JH, Spaander MC, Leebeek FW, Janssen HL. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost. 2011;9:2208–2214.PubMedCrossRef
Metadata
Title
An Association of Myeloproliferative Neoplasms and Obliterative Portal Venopathy
Authors
Jillian E. Mayer
Thomas D. Schiano
Maria Isabel Fiel
Ronald Hoffman
John O. Mascarenhas
Publication date
01-07-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-3018-x

Other articles of this Issue 7/2014

Digestive Diseases and Sciences 7/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.